Target- and drug discovery
Structural protein changes that lead to altered function are highly prevalent in disease. Very often, they present interesting potential targets against which small-molecule drugs can be developed that restore the diseased protein’s functionality or prevent disease progression.
What do we offer?
Using (multimodal) data mining and data analytics, we support the discovery and identification of promising druggable targets and corresponding small molecule drug candidates. We optimize novel leads by using structural modelling, molecule modelling, structure-activity relationships (SAR), virtual high-throughput screening and machine- and deep learning algorithms.
We also support further preclinical development by mode-of-action (MOA) assessment, functional testing and prediction, multi-omics data analysis, image analysis and much more. Safety and ADME (absorption, disruption, metabolism and excretion) are also studied.
Our expertise covers the complete preclinical drug development pipeline. We assist in the transition to clinical development by correlating and integration preclinical and clinical data.
For our continued support during clinical drug development see the full list of our clinical data services and clinical data integration and management solutions.